Biodesix Q2 core lung diagnostics revenue up 58% YoY to $11.4M; raises $27.5M

BIODESIX INC

2023-Q2 EPS reported -$0.41 revenue$20,928,000

Core lung diagnostic revenue $11.4M (+58% YoY, +33% QoQ); gross margin 73% vs 64% in Q2 2022.
Net loss $13.4M improved 16% YoY; cash burn reduced 56% QoQ to $7.9M.
Raised $27.5M in private placement post-quarter from largest shareholders, board, and management.
Reaffirmed FY2023 total revenue guidance of $52-55M.
Achieved primary endpoint of ORACLE study: 74% reduction in unnecessary procedures using Nodify XL2.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

BIODESIX INC updated its second quarter ended June 30, 2023 guidance (reaffirmed).

Period: second quarter ended June 30, 2023
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On August 7, 2023, Biodesix, Inc. (the Company) issued a press release announcing the financial and operating results of the Company for the second quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

BIODESIX INC filing history →

Source: SEC EDGAR

accession 0000950170-23-039049

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.